Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients

British Journal of Haematology

Volumn 140, Issue 1, 2008, Pages 71-79

  Kim, Dong Hwan ^a,c,d   Lee, Nan Young ^a   Lee, Myung Hoon ^a   Sohn, Sang Kyun ^a   Do, Young Rok ^b   Park, Jae Yong ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Keimyung University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Acute myeloid leukaemia; Single nucleotide polymorphism; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36849067425     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06887.x     Document Type: Article

References (47)

1. Aguayo, A. (2004) The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Current Hematology Reports, 3, 184 191.
2. Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B. Albitar, M. (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94, 3717 3721.
3. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., Freireich, E. Albitar, M. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, 2240 2245.
4. Aguayo, A., Kantarjian, H.M., Estey, E.H., Giles, F.J., Verstovsek, S., Manshouri, T., Gidel, C., O'Brien, S., Keating, M.J. Albitar, M. (2002) Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer, 95, 1923 1930.
5. Aguayo, A., Giles, F. Albitar, M. (2003) Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leukemia & Lymphoma, 44, 213 222.
6. Awata, T., Kurihara, S., Takata, N., Neda, T., Iizuka, H., Ohkubo, T., Osaki, M., Watanabe, M., Nakashima, Y., Inukai, K., Inoue, I., Kawasaki, I., Mori, K., Yoneya, S. Katayama, S. (2005) Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochemical and Biophysical Research Communications, 333, 679 685.
7. Barrett, J.C., Fry, B., Maller, J. Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263 265.
8. Bellamy, W.T., Richter, L., Frutiger, Y. Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728 733.
9. de Bont, E.S., Fidler, V., Meeuwsen, T., Scherpen, F., Hahlen, K. Kamps, W.A. (2002) Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clinical Cancer Research, 8, 2856 2861.
10. Brogan, I.J., Khan, N., Isaac, K., Hutchinson, J.A., Pravica, V. Hutchinson, I.V. (1999) Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Human Immunology, 60, 1245 1249.
11. Daly, M.J., Rioux, J.D., Schaffner, S.F., Hudson, T.J. Lander, E.S. (2001) High-resolution haplotype structure in the human genome. Nature Genetics, 29, 229 232.
12. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., Hicklin, D.J., Witte, L., Moore, M.A. Rafii, S. (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. Journal of Clinical Investigation, 106, 511 521.
13. Dias, S., Shmelkov, S.V., Lam, G. Rafii, S. (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood, 99, 2532 2540.
14. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N., Stockschlader, M. Hossfeld, D.K. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, 1870 1875.
15. Freathy, R.M., Weedon, M.N., Shields, B., Hitman, G.A., Walker, M., McCarthy, M.I., Hattersley, A.T. Frayling, T.M. (2006) Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. JOP, 7, 295 302.
16. Girnita, D.M., Webber, S.A., Ferrell, R., Burckart, G.J., Brooks, M.M., McDade, K.K., Chinnock, R., Canter, C., Addonizio, L., Bernstein, D., Kirklin, J.K., Girnita, A.L. Zeevi, A. (2006) Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation, 82, 1774 1780.
17. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322 2333.
18. Han, S.W., Kim, G.W., Seo, J.S., Kim, S.J., Sa, K.H., Park, J.Y., Lee, J., Kim, S.Y., Goronzy, J.J., Weyand, C.M. Kang, Y.M. (2004) VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford), 43, 1173 1177.
19. Hazar, B., Paydas, S., Zorludemir, S., Sahin, B. Tuncer, I. (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leukemia & Lymphoma, 44, 2089 2093.
20. Hussong, J.W., Rodgers, G.M. Shami, P.J. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, 309 313.
21. Illmer, T., Schuler, U.S., Thiede, C., Schwarz, U.I., Kim, R.B., Gotthard, S., Freund, D., Schakel, U., Ehninger, G. Schaich, M. (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Research, 62, 4955 4962.
22. Kataoka, N., Cai, Q., Wen, W., Shu, X.O., Jin, F., Gao, Y.T. Zheng, W. (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiology, Biomarkers and Prevention, 15, 1148 1152.
23. Katoh, O., Takahashi, T., Oguri, T., Kuramoto, K., Mihara, K., Kobayashi, M., Hirata, S. Watanabe, H. (1998) Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Research, 58, 5565 5569.
24. Kim, J.G., Sohn, S.K., Kim, D.H., Baek, J.H., Lee, N.Y., Suh, J.S., Chae, S.C., Lee, K.S. Lee, K.B. (2005) Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leukemia & Lymphoma, 46, 885 891.
25. Kim, D.H., Park, J.Y., Sohn, S.K., Lee, N.Y., Baek, J.H., Jeon, S.B., Kim, J.G., Suh, J.S., Do, Y.R. Lee, K.B. (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. International Journal of Cancer, 118, 2195 2201.
26. Klagsbrun, M. D'Amore, P.A. (1996) Vascular endothelial growth factor and its receptors. Cytokine and Growth Factor Reviews, 7, 259 270.
27. Koomagi, R., Zintl, F., Sauerbrey, A. Volm, M. (2001) Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clinical Cancer Research, 7, 3381 3384.
28. Koukourakis, M.I., Papazoglou, D., Giatromanolaki, A., Bougioukas, G., Maltezos, E. Sivridis, E. (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer, 46, 293 298.
29. Krippl, P., Langsenlehner, U., Renner, W., Yazdani-Biuki, B., Wolf, G., Wascher, T.C., Paulweber, B., Haas, J. Samonigg, H. (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. International Journal of Cancer, 106, 468 471.
30. Kuramoto, K., Sakai, A., Shigemasa, K., Takimoto, Y., Asaoku, H., Tsujimoto, T., Oda, K., Kimura, A., Uesaka, T., Watanabe, H. Katoh, O. (2002) High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. British Journal of Haematology, 116, 158 161.
31. Lee, J.J., Chung, I.J., Park, M.R., Ryang, D.W., Park, C.S. Kim, H.J. (2001) Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leukemia Research, 25, 1067 1073.
32. Lee, S.J., Lee, S.Y., Jeon, H.S., Park, S.H., Jang, J.S., Lee, G.Y., Son, J.W., Kim, C.H., Lee, W.K., Kam, S., Park, R.W., Park, T.I., Kang, Y.M., Kim, I.S., Jung, T.H. Park, J.Y. (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiology, Biomarkers and Prevention, 14, 571 575.
33. Mitelman, F. (1995) ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. S Karger, Basel, Switzerland.
34. Monzo, M., Brunet, S., Urbano-Ispizua, A., Navarro, A., Perea, G., Esteve, J., Artells, R., Granell, M., Berlanga, J., Ribera, J.M., Bueno, J., Llorente, A., Guardia, R., Tormo, M., Torres, P., Nomdedeu, J.F., Montserrat, E. Sierra, J. (2006) Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood, 107, 4871 4879.
35. Nam, E.J., Han, S.W., Kim, S.U., Cho, J.H., Sa, K.H., Lee, W.K., Park, J.Y. Kang, Y.M. (2005) Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population. Human Immunology, 66, 1068 1073.
36. Niitsu, N., Okamato, M., Nakamine, H., Yoshino, T., Tamaru, J., Nakamura, S., Higashihara, M. Hirano, M. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. European Journal of Haematology, 68, 91 100.
37. Prior, S.J., Hagberg, J.M., Paton, C.M., Douglass, L.W., Brown, M.D., McLenithan, J.C. Roth, S.M. (2006) DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. American Journal of Physiology. Heart and Circulatory Physiology, 290, H1848 H1855.
38. Renner, W., Kotschan, S., Hoffmann, C., Obermayer-Pietsch, B. Pilger, E. (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. Journal of Vascular Research, 37, 443 448.
39. Salven, P., Teerenhovi, L. Joensuu, H. (1997) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood, 90, 3167 3172.
40. Shahbazi, M., Fryer, A.A., Pravica, V., Brogan, I.J., Ramsay, H.M., Hutchinson, I.V. Harden, P.N. (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. Journal of the American Society of Nephrology, 13, 260 264.
41. Stephens, M., Smith, N.J. Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics, 68, 978 989.
42. Stevens, A., Soden, J., Brenchley, P.E., Ralph, S. Ray, D.W. (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Research, 63, 812 816.
43. Thomas, K.A. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. Journal of Biological Chemistry, 271, 603 606.
44. Thomas, D.A., Giles, F.J., Cortes, J., Albitar, M. Kantarjian, H.M. (2001) Antiangiogenic therapy in leukemia. Acta Haematologica, 106, 190 207.
45. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J.C. Abraham, J.A. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. Journal of Biological Chemistry, 266, 11947 11954.
46. Vincenti, V., Cassano, C., Rocchi, M. Persico, G. (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation, 93, 1493 1495.
47. Watson, C.J., Webb, N.J., Bottomley, M.J. Brenchley, P.E. (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine, 12, 1232 1235.